Movement Alert｜Iovance Biotherapeutics, Inc. After-Hours Rise 7.97%, webcast to present positive mNSCLC TIL data and precision medicine strategy

Market Focus10-29

On October 29, Iovance Biotherapeutics, Inc. rose 7.97% in After-Hours Trading, trading at $15.84/share, with Turnover of $6.0165 million.

The direct catalyst was the company’s announcement that it will host a webcast to discuss positive data for tumor-infiltrating lymphocyte therapy in metastatic non-small cell lung cancer and its broader precision medicine strategy.

Background context shows Iovance Biotherapeutics, Inc. has recently drawn added attention ahead of its November 5 third-quarter results, after previously raising full-year revenue guidance to $410 million-$420 million from $350 million-$370 million on strong demand for Amtagvi and Proleukin. Earlier clinical updates also included a 62.5% overall response rate and 29.2% complete response rate in a Phase 2 frontline advanced melanoma trial of lifileucel plus pembrolizumab, reinforcing investor focus on both commercial execution and pipeline expansion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment